Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...